BPC-157
BPC-157 is an investigational 15-amino-acid peptide commonly described as a “body protection compound” derived from gastric juice research. It has attracted attention for possible effects on tissue repair, angiogenesis, gut protection, and inflammation in animal models, but human evidence is very limited and it is not FDA approved for medical or wellness use.
Overview
BPC-157 is also called a stable gastric pentadecapeptide. Most of the published literature involves preclinical models, especially tendon, ligament, muscle, nerve, and gastrointestinal injury models. Reviews consistently note that human data are sparse and that many of the bold claims made online go far beyond the available clinical evidence.
What it is
BPC-157 is a pentadecapeptide, meaning it contains 15 amino acids. PubChem identifies it as a peptide with the molecular formula C62H98N16O22.
Mechanism (high level)
Its exact mechanism in humans is not established. Preclinical literature suggests possible effects on angiogenesis, nitric oxide signaling, cytoprotection, inflammatory pathways, and tissue repair signaling, especially in the gut and musculoskeletal system. These mechanisms remain largely based on animal and laboratory research rather than definitive human proof.
Quick facts
- Dosage
- There is no universally accepted evidence-based human dose for BPC-157. Published human efficacy dosing is not well established in peer-reviewed literature, and existing reviews emphasize that human trial data are extremely limited.
- Route
- Human route data are limited. In practice, BPC-157 is commonly marketed as oral or injectable, but robust peer-reviewed human evidence for standardized use by either route is lacking. Preclinical literature has used oral and parenteral routes, but that should not be treated as established human guidance.
- Cycle
- No standardized cycle has been established in humans.
- Storage
- Follow manufacturer or compounding-pharmacy instructions exactly Protect from heat and light Do not use beyond labeled storage limits Because marketed products vary widely and BPC-157 is not an approved standardized drug product, storage should follow the exact dispensing source rather than a generic rule.
Research indications
- Tendon repair research
- Ligament healing research
- Muscle recovery research
- Gastrointestinal protection research
- Ulcerative colitis research
- Inflammation modulation research
- Angiogenesis research
- Nerve repair research
Research protocols (education)
3 pilot studies
Preclinical tendon, ligament, muscle, and gut injury models dominate the literature A Phase II ulcerative colitis program has been referenced in reviews, but published peer-reviewed outcome data are limited or absent Only a few small human pilot reports have been described in reviews, with major limitations. That is the cleanest evidence-based way to phrase it. A 2025 narrative review said only three pilot studies had examined BPC-157 in humans, while older reviews referenced Phase II ulcerative colitis work.
Interactions
Often avoided with
- Pregnancy
- Breastfeeding
- Unsupervised use of compounded injectable product
- Use in competitive athletes subject to anti-doping rules
- Use with caution in people relying on proven treatment for serious injury or disease
- Use with caution when product source or purity is uncertain
Often combined with
- Clinician-supervised investigational discussion
- Review of preclinical research
- Use only with clear understanding that it is non-approved
- Use only with verified sourcing and oversight
Use only manufacturer or compounding-pharmacy instructions Do not self-reconstitute unless official product directions are provided Sterile handling and product verification are essential Do not assume all marketed BPC-157 products are equivalent
Side effects & safety
- Human safety data are limited
- Compounded product quality may vary
- Potential contamination or impurity risk
- Possible immunogenicity risk with compounded products
- Long-term human safety not established
- Potential risk from delaying proven medical treatment
Regulatory notes
- Not an FDA-approved drug
- FDA says compounded drugs containing BPC-157 may present significant safety risks
- Not an approved dietary ingredient
- WADA prohibits BPC-157 under S0 Non-Approved Substances
- Human clinical evidence remains limited
FAQ
What is BPC-157?
BPC-157 is an investigational 15-amino-acid peptide often described as a body protection compound. Most of its published support comes from animal studies rather than robust human trials.
Is BPC-157 FDA approved?
No. BPC-157 is not an FDA-approved drug. FDA has also warned that compounded drugs containing BPC-157 may present significant safety risks
What is BPC-157 used for?
It is commonly discussed for tissue repair, gut support, and recovery, but those are investigational uses and are not established approved indications.
Is BPC-157 banned in sports?
Yes. WADA lists BPC-157 under S0 Non-Approved Substances, prohibited at all times.
Does BPC-157 have strong human evidence?
No. Reviews say human evidence is limited, with only a few small pilot studies and no strong body of controlled clinical data to support most popular claims.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.